Aggrastat® has the lowest per-patient acquisition costs of any GP IIb/IIIa inhibitor, including generics.

Wholesale Acquisition Costs

Aggrastat® pricing above does not include any discounts. Actual costs are significantly lower due to contract and wholesaler discounts.

Speak to a product specialist to learn more about our: Competitive Discounting Program and Generic Protection

Aggrastat Product Format

*WAC=Wholesale acquisition cost. This pricing does not account for any manufacturer discounts or for those hospitals that are able to purchase at PHS 340B pricing for eligible outpatient use.

Costs based on shared labeled use of products, according to WAC pricing as of May 2017. Cost of generic eptifibatide based on average WAC. Cost of heparin not included. Costs subject to change and may not reflect actual costs to patients. Cost comparisons do not imply comparable efficacy, safety or product interchangeability. Aggrastat® and Integrilin (eptifibatide) have not been compared in head-to-head clinical trials. A true cost effectiveness analysis compares the costs and financial savings associated with a therapy, including the costs of the therapy itself, side effects, medical/hospital costs, and savings from avoided illness and disability to the health effect of the therapy. This analysis only compares the acquisition costs of the therapies themselves.



Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).


  • Known hypersensitivity to any component of Aggrastat®.
  • History of thrombocytopenia with prior exposure to Aggrastat®.
  • Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.

Warnings and Precautions:

  • Aggrastat® can cause serious bleeding. Most bleeding associated with Aggrastat® occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Concomitant use of fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding. If bleeding cannot be controlled, discontinue Aggrastat®.
  • Thrombocytopenia: discontinue Aggrastat® and heparin.

Adverse Reactions:

  • Bleeding is the most commonly reported adverse reaction.

For additional information, refer to the full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA.

or call 1-800-FDA-1088.

Unite Interactive